File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Therapy-related lymphomas in patients with autoimmune diseases after treatment with disease-modifying anti-rheumatic drugs

TitleTherapy-related lymphomas in patients with autoimmune diseases after treatment with disease-modifying anti-rheumatic drugs
Authors
Au, WYMa, ESKChoy, CChung, LPFung, TKLiang, RKwong, YL
KeywordsAutoimmune diseases
Azathioprine
Cyclophosphamide
Methotrexate
Therapy-related lymphoma
Issue Date2006
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/35105
Citation
American Journal Of Hematology, 2006, v. 81 n. 1, p. 5-11 How to Cite?
DOI: http://dx.doi.org/10.1002/ajh.20508
AbstractTen patients developing lymphomas after disease modifying anti-rheumatic drugs (DMARD) (methotrexate, n = 3, mean cumulative dose = 3.4 g; cyclophosphamide, n = 2, mean dose = 70 g; azathioprine, n = 6, mean dose = 243 g) were investigated. Methotrexate-related lymphomas were Epstein-Barr virus (EBV)-positive, had infrequent aberrant methylation of p15 and p16, and responded well to methotrexate withdrawal or anti-CD20 antibody (rituximab) alone without concomitant chemotherapy, implying that defective immunosurveillance was important in lymphomagenesis. However, 75% of cyclophosphamide/azathioprine-related lymphomas were EBV-negative, had frequent p15 and p16 methylation, and responded poorly to drug withdrawal and chemotherapy, implying that direct drug-induced mutagenesis might be involved in lymphomagenesis. © 2005 Wiley-Liss, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/77400
ISSN
0361-8609
2023 Impact Factor: 10.1
2023 SCImago Journal Rankings: 2.607
ISI Accession Number ID
WOS:000234474900002
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorAu, WYen_HK
dc.contributor.authorMa, ESKen_HK
dc.contributor.authorChoy, Cen_HK
dc.contributor.authorChung, LPen_HK
dc.contributor.authorFung, TKen_HK
dc.contributor.authorLiang, Ren_HK
dc.contributor.authorKwong, YLen_HK
dc.date.accessioned2010-09-06T07:31:29Z-
dc.date.available2010-09-06T07:31:29Z-
dc.date.issued2006en_HK
dc.identifier.citationAmerican Journal Of Hematology, 2006, v. 81 n. 1, p. 5-11en_HK
dc.identifier.issn0361-8609en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77400-
dc.description.abstractTen patients developing lymphomas after disease modifying anti-rheumatic drugs (DMARD) (methotrexate, n = 3, mean cumulative dose = 3.4 g; cyclophosphamide, n = 2, mean dose = 70 g; azathioprine, n = 6, mean dose = 243 g) were investigated. Methotrexate-related lymphomas were Epstein-Barr virus (EBV)-positive, had infrequent aberrant methylation of p15 and p16, and responded well to methotrexate withdrawal or anti-CD20 antibody (rituximab) alone without concomitant chemotherapy, implying that defective immunosurveillance was important in lymphomagenesis. However, 75% of cyclophosphamide/azathioprine-related lymphomas were EBV-negative, had frequent p15 and p16 methylation, and responded poorly to drug withdrawal and chemotherapy, implying that direct drug-induced mutagenesis might be involved in lymphomagenesis. © 2005 Wiley-Liss, Inc.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www3.interscience.wiley.com/cgi-bin/jhome/35105en_HK
dc.relation.ispartofAmerican Journal of Hematologyen_HK
dc.rightsAmerican Journal of Hematology. Copyright © John Wiley & Sons, Inc.en_HK
dc.subjectAutoimmune diseasesen_HK
dc.subjectAzathioprineen_HK
dc.subjectCyclophosphamideen_HK
dc.subjectMethotrexateen_HK
dc.subjectTherapy-related lymphomaen_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAntibodies, Monoclonal - administration & dosageen_HK
dc.subject.meshAntibodies, Monoclonal, Murine-Deriveden_HK
dc.subject.meshAntineoplastic Agents - administration & dosageen_HK
dc.subject.meshAntirheumatic Agents - administration & dosage - adverse effectsen_HK
dc.subject.meshAutoimmune Diseases - complications - drug therapy - metabolismen_HK
dc.subject.meshBurkitt Lymphoma - drug therapy - etiology - metabolism - virologyen_HK
dc.subject.meshCell Transformation, Viral - drug effectsen_HK
dc.subject.meshCyclin-Dependent Kinase Inhibitor p15 - metabolismen_HK
dc.subject.meshCyclin-Dependent Kinase Inhibitor p16 - metabolismen_HK
dc.subject.meshDNA Methylation - drug effectsen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHerpesvirus 4, Human - metabolismen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshMutagenesis - drug effectsen_HK
dc.subject.meshRetrospective Studiesen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleTherapy-related lymphomas in patients with autoimmune diseases after treatment with disease-modifying anti-rheumatic drugsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0361-8609&volume=81&issue=1&spage=5&epage=11&date=2005&atitle=Therapy-related+lymphomas+in+patients+with+autoimmune+diseases+after+treatment+with+disease-modifying+anti-rheumatic+drugsen_HK
dc.identifier.emailChung, LP: lpchung@hkucc.hku.hken_HK
dc.identifier.emailLiang, R: rliang@hku.hken_HK
dc.identifier.emailKwong, YL: ylkwong@hku.hken_HK
dc.identifier.authorityChung, LP=rp00249en_HK
dc.identifier.authorityLiang, R=rp00345en_HK
dc.identifier.authorityKwong, YL=rp00358en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/ajh.20508en_HK
dc.identifier.pmid16369970-
dc.identifier.scopuseid_2-s2.0-30444438731en_HK
dc.identifier.hkuros119518en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-30444438731&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume81en_HK
dc.identifier.issue1en_HK
dc.identifier.spage5en_HK
dc.identifier.epage11en_HK
dc.identifier.isiWOS:000234474900002-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridAu, WY=7202383089en_HK
dc.identifier.scopusauthoridMa, ESK=7202039934en_HK
dc.identifier.scopusauthoridChoy, C=7202840937en_HK
dc.identifier.scopusauthoridChung, LP=24315879100en_HK
dc.identifier.scopusauthoridFung, TK=54389057000en_HK
dc.identifier.scopusauthoridLiang, R=26643224900en_HK
dc.identifier.scopusauthoridKwong, YL=7102818954en_HK
dc.identifier.issnl0361-8609-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats